Dubai Telegraph - Trial of new Covid treatment yields encouraging results: study

EUR -
AED 3.896782
AFN 71.970942
ALL 98.005181
AMD 410.245014
ANG 1.910392
AOA 969.150107
ARS 1058.535585
AUD 1.625105
AWG 1.911243
AZN 1.804916
BAM 1.952226
BBD 2.140282
BDT 126.668083
BGN 1.954125
BHD 0.39988
BIF 3130.34894
BMD 1.060918
BND 1.418709
BOB 7.350404
BRL 6.098794
BSD 1.060009
BTN 89.509273
BWP 14.421276
BYN 3.468912
BYR 20793.984215
BZD 2.136589
CAD 1.480871
CDF 3043.772641
CHF 0.937002
CLF 0.037907
CLP 1045.969635
CNY 7.661842
COP 4706.760764
CRC 542.432423
CUC 1.060918
CUP 28.114315
CVE 110.062449
CZK 25.385671
DJF 188.763289
DKK 7.459582
DOP 63.876059
DZD 141.570939
EGP 52.207642
ETB 131.000325
FJD 2.400856
GBP 0.832847
GEL 2.906642
GHS 17.277204
GMD 75.853327
GNF 9135.746941
GTQ 8.190926
GYD 221.749817
HKD 8.252734
HNL 26.751282
HTG 139.425239
HUF 411.004238
IDR 16737.512871
ILS 3.989583
INR 89.539798
IQD 1388.583814
IRR 44669.934186
ISK 147.520817
JMD 168.439542
JOD 0.752299
JPY 164.527633
KES 137.06364
KGS 91.448653
KHR 4295.439124
KMF 488.419938
KRW 1493.349953
KWD 0.326234
KYD 0.883299
KZT 526.01683
LAK 23242.540542
LBP 94922.679318
LKR 309.967089
LRD 199.802298
LSL 19.152137
LTL 3.132613
LVL 0.641738
LYD 5.135839
MAD 10.515649
MDL 18.974154
MGA 4955.161109
MKD 61.501816
MMK 3445.818857
MOP 8.49301
MRU 42.123861
MUR 50.064526
MVR 16.402021
MWK 1837.721918
MXN 21.861851
MYR 4.72746
MZN 67.819132
NAD 19.151596
NGN 1778.681478
NIO 39.010598
NOK 11.769899
NPR 143.222523
NZD 1.790898
OMR 0.408483
PAB 1.059939
PEN 4.005911
PGK 4.258364
PHP 62.296049
PKR 294.599601
PLN 4.351472
PYG 8282.226373
QAR 3.864488
RON 4.975918
RSD 116.986352
RUB 103.700317
RWF 1454.705134
SAR 3.986063
SBD 8.859994
SCR 14.916358
SDG 638.142533
SEK 11.580918
SGD 1.420892
SLE 24.18896
SOS 605.819355
SRD 37.381452
STD 21958.851549
SVC 9.275193
SZL 19.142853
THB 36.855747
TJS 11.267165
TMT 3.713211
TND 3.332367
TOP 2.48477
TRY 36.47689
TTD 7.203151
TWD 34.468683
TZS 2825.997726
UAH 43.903187
UGX 3894.795581
USD 1.060918
UYU 44.68818
UZS 13571.98253
VES 47.606636
VND 26894.260197
XAF 654.789004
XCD 2.867183
XDR 0.798576
XOF 654.789004
XPF 119.331742
YER 264.990671
ZAR 19.19911
ZMK 9549.525686
ZMW 28.858523
ZWL 341.615022
  • RBGPF

    59.3400

    59.34

    +100%

  • RYCEF

    -0.0500

    7.11

    -0.7%

  • CMSC

    -0.1800

    24.54

    -0.73%

  • NGG

    -1.2400

    62.9

    -1.97%

  • RIO

    -1.4000

    61.2

    -2.29%

  • SCS

    0.0200

    13.67

    +0.15%

  • BTI

    0.0900

    35.24

    +0.26%

  • RELX

    -1.2100

    46.59

    -2.6%

  • CMSD

    -0.2100

    24.75

    -0.85%

  • GSK

    -0.8300

    35.52

    -2.34%

  • VOD

    -0.8500

    8.47

    -10.04%

  • BCC

    -2.0100

    141.13

    -1.42%

  • BP

    -0.7600

    28.16

    -2.7%

  • AZN

    0.4000

    65.19

    +0.61%

  • BCE

    -0.1600

    27.69

    -0.58%

  • JRI

    -0.3000

    13.22

    -2.27%

Trial of new Covid treatment yields encouraging results: study
Trial of new Covid treatment yields encouraging results: study / Photo: SCOTT OLSON - GETTY IMAGES NORTH AMERICA/AFP/File

Trial of new Covid treatment yields encouraging results: study

A single-injection antiviral treatment for newly-infected Covid-19 patients reduced the risk of hospitalization by half in a large-scale clinical trial, according to a study published on Wednesday.

Text size:

Stanford University professor Jeffrey Glenn, coauthor of the study published in the New England Journal of Medicine (NEJM), said the new drug "showed profound benefits for vaccinated and unvaccinated people alike."

While the number of Americans dying daily of coronavirus has fallen to around 500, treatments for the disease remain limited. One of the most common, Paxlovid made by Pfizer, involves taking 30 pills over five days.

The new treatment involves a single dose of pegylated lambda-interferon, a synthetic version of a naturally occurring protein that infected cells secrete to defend against viral infection.

"What it does is it binds receptors on the surfaces of cells that activate our own antiviral defense mechanisms," said Glenn, a professor of medicine, microbiology and immunology who heads the Stanford Biosecurity and Pandemic Preparedness Initiative.

"So if a virus has infected the cell it will turn on processes that aim to destroy the virus's replication," he said. "It will also send signals to neighboring cells to warn them viruses are on their way and get ready to defend yourself."

Receptors for interferon lambda are primarily in the linings of the lungs, airways and intestine -- the main places Covid strikes.

"We're turning on these antiviral mechanisms in the cells, the lung, where the infection is happening," Glenn said.

The Phase 3 trial of the drug, conducted between June 2021 and February 2022, involved nearly 2,000 patients with Covid symptoms in Brazil and Canada, about 85 percent of whom had been vaccinated.

A total of 931 newly-infected Covid patients were given a single injection of interferon lambda while 1,018 participants were given a placebo.

The risk of Covid-19–related hospitalization or death from any cause was 47 percent lower in the interferon group than in the placebo group, according to the researchers.

Twenty-five of the 931 people who received the injection within seven days of exhibiting Covid symptoms were hospitalized compared with 57 of the 1,018 who received the placebo.

Vaccinated patients treated with interferon lambda experienced a 51 percent reduction in hospitalization relative to the placebo group.

There was an 89 percent reduction in hospitalization among unvaccinated patients treated within the first three days of the onset of Covid symptoms compared with the placebo group.

- Developed for hepatitis D -

Glenn said interferon lambda proved effective against all Covid variants tested, including Omicron, and side effects in the group receiving the injections were no greater than among the placebo recipients.

Glenn is the founder of a small biotechnology company called Eiger Biopharmaceuticals that acquired interferon lambda to develop drugs for hepatitis delta virus.

"When Covid came, I said this would be the perfect drug for Covid," said Glenn, who left the Palo Alto-based company but remains on the board of directors and is an equity holder.

Eiger sought an emergency use authorization for interferon lambda from the US Federal Drug Administration (FDA) for Covid treatment last year but it was not granted.

That was "very frustrating," Glenn said, but he was hopeful publication of the study in the NEJM "will help encourage regulators here and around the world to find a way to get lambda into patients as soon as possible."

F.Damodaran--DT